ReviewNature reviews. Urology2015
Testosterone therapy and prostate cancer--safety concerns are well founded.
Review in Nature reviews. Urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Cardiovascular and prostate cancer risk associated to testosterone replacement therapy - a systematic review and meta-analysis of 41 randomized controlled trials.International journal of impotence research · 2026Review
- Improvement of Late-Onset Hypogonadism Symptoms of FermentedNutrients · 2024Article
- Editorial: Aging and male hypogonadism.Frontiers in endocrinology · 2023Article
- Testosterone Deficiency is Not Protective Against the Development of Adenocarcinoma of the Prostate in a Type 1 Diabetic Patient.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022Article
- CXCR4-SF1 bifunctional adipose-derived stem cells benefit for the treatment of Leydig cell dysfunction-related diseases.Journal of cellular and molecular medicine · 2020Article
- Differentiation of human umbilical cord mesenchymal stem cells into Leydig-like cells with defined molecular compounds.Human cell · 2020Article
- Stem Leydig Cells in the Adult Testis: Characterization, Regulation and Potential Applications.Endocrine reviews · 2020Review
- Testosterone Therapy in Relation to Prostate Cancer in a U.S. Commercial Insurance Claims Database.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Restorative functions of Autologous Stem Leydig Cell transplantation in a Testosterone-deficient non-human primate model.Theranostics · 2020Article
- Differentiation of human adipose derived stem cells into Leydig-like cells with molecular compounds.Journal of cellular and molecular medicine · 2019Article
- Differentiation of human induced pluripotent stem cells into Leydig-like cells with molecular compounds.Cell death & disease · 2019Article
- Role of Testosterone in the Treatment of Cardiovascular Disease.European cardiology · 2017Review
- Transdifferentiation of adult rat stem Leydig cells into prostatic and uterine epithelium, but not epidermis.Andrology · 2017Article
- Low free and bioavailable testosterone levels may predict pathologically-proven high-risk prostate cancer: a prospective, clinical trial.Turkish journal of urology · 2017Article
- Leydig cell stem cells: Identification, proliferation and differentiation.Molecular and cellular endocrinology · 2017Review
- Transplantation of alginate-encapsulated seminiferous tubules and interstitial tissue into adult rats: Leydig stem cell differentiation in vivo?Molecular and cellular endocrinology · 2016Article
- The Potential of Gonadal Hormone Signalling Pathways as Therapeutics for Dementia.Journal of molecular neuroscience : MN · 2016Review
- Do we have enough evidences that make you safe to treat a man with hypogonadism one year after a radical prostatectomy for prostate cancer? | Opinion: Not Yet.International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Testosterone is a potent hormone with a variety of physiological effects. The diagnosis of androgen deficiency has increased dramatically over the past decade, along with the widespread use of testosterone supplementation therapy (TST). The long-term effects of TST are uncertain, and the risk of overdiagnosis and overtreatment of men who have a normal age-related decline in testosterone is substantial. The biology of the androgen receptor (AR) pathway is complex, and the saturation model does not take the heterogeneity of human prostate cancer into account. Large-scale trials to confirm the safety of testosterone with respect to the risks of prostate cancer and cardiovascular disease with reasonable confidence limits have not been done, and existing data are insufficient to exclude these adverse events. Instead, evidence suggests that prostate cancer could, in fact, be stimulated by TST, and that the risk of cardiovascular events is increased. Overall, TST seems to impose significant risks, and should be used with caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.